Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helmut R Maecke

Showing results (31-40 of 86) with videos related to

Pageof 9
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 7, 2004
Radiation therapy of small cell lung cancer with 177Lu-DOTA-Tyr3-octreotate in an animal modelAnneli Schmitt, Peter Bernhardt, Ola Nilsson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 11, 2013
Radioimmunotherapy with 177Lu-DOTA-rituximab: final results of a phase I/II Study in 31 patients with relapsing follicular, mantle cell, and other indolent B-cell lymphomasFlavio Forrer, Catharina Oechslin-Oberholzer, Benedetta Campana, et al.
Journal of Medicinal Chemistry|June 12, 2008
Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargetingRenzo Cescato, Judith Erchegyi, Beatrice Waser, et al.
Nuclear Medicine and Biology|May 1, 2014
PEG spacers of different length influence the biological profile of bombesin-based radiolabeled antagonistsMazen Jamous, Maria L Tamma, Eleni Gourni, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 6, 2005
Species differences of bombesin analog interactions with GRP-R define the choice of animal models in the development of GRP-R-targeting drugsTheodosia Maina, Berthold A Nock, Hanwen Zhang, et al.
Nuclear Medicine and Biology|November 21, 2016
Approaches to improve metabolic stability of a statine-based GRP receptor antagonistIlinca Popp, Luigi Del Pozzo, Beatrice Waser, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 8, 2009
In vitro characterization of (177)Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry studyFlavio Forrer, Jianhua Chen, Melpomeni Fani, et al.
Molecular Imaging|November 4, 2017
Radiochemistry and Preclinical PET Imaging of <sup>68</sup>Ga-Desferrioxamine Radiotracers Targeting Prostate-Specific Membrane AntigenEleni Gourni, Luigi Del Pozzo, Mark Bartholomä, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 8, 2002
Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOCChristian Waldherr, Miklos Pless, Helmut R Maecke, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 4, 2014
Does imaging αvβ3 integrin expression with PET detect changes in angiogenesis during bevacizumab therapy?Svetlana N Rylova, Enikö Barnucz, Melpomeni Fani, et al.
Pageof 9

Showing results (31-40 of 86) with videos related to

Sort By:
Pageof 9
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 7, 2004
Radiation therapy of small cell lung cancer with 177Lu-DOTA-Tyr3-octreotate in an animal modelAnneli Schmitt, Peter Bernhardt, Ola Nilsson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 11, 2013
Radioimmunotherapy with 177Lu-DOTA-rituximab: final results of a phase I/II Study in 31 patients with relapsing follicular, mantle cell, and other indolent B-cell lymphomasFlavio Forrer, Catharina Oechslin-Oberholzer, Benedetta Campana, et al.
Journal of Medicinal Chemistry|June 12, 2008
Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargetingRenzo Cescato, Judith Erchegyi, Beatrice Waser, et al.
Nuclear Medicine and Biology|May 1, 2014
PEG spacers of different length influence the biological profile of bombesin-based radiolabeled antagonistsMazen Jamous, Maria L Tamma, Eleni Gourni, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 6, 2005
Species differences of bombesin analog interactions with GRP-R define the choice of animal models in the development of GRP-R-targeting drugsTheodosia Maina, Berthold A Nock, Hanwen Zhang, et al.
Nuclear Medicine and Biology|November 21, 2016
Approaches to improve metabolic stability of a statine-based GRP receptor antagonistIlinca Popp, Luigi Del Pozzo, Beatrice Waser, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 8, 2009
In vitro characterization of (177)Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry studyFlavio Forrer, Jianhua Chen, Melpomeni Fani, et al.
Molecular Imaging|November 4, 2017
Radiochemistry and Preclinical PET Imaging of <sup>68</sup>Ga-Desferrioxamine Radiotracers Targeting Prostate-Specific Membrane AntigenEleni Gourni, Luigi Del Pozzo, Mark Bartholomä, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 8, 2002
Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOCChristian Waldherr, Miklos Pless, Helmut R Maecke, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 4, 2014
Does imaging αvβ3 integrin expression with PET detect changes in angiogenesis during bevacizumab therapy?Svetlana N Rylova, Enikö Barnucz, Melpomeni Fani, et al.
Pageof 9